The Role of Netrin -1 in Acute Coronary Syndrome (ACS-NETRİN-1)

The Effect of Serum Netrin-1 Levels on Diagnosis and Prognosis in Patients Presenting to the Emergency Department With Acute Coronary Syndrome

In our study, Netrin -1; We found that patients with ACS increased at the time of admission, decreased TIMI 3 flow after angiography, and higher risk groups in high risk groups such as TIMI and GRACE were found to have higher Netrin-1 levels.

Study Overview

• Status: Completed
• Conditions: Acute Coronary Syndrome
• Intervention / Treatment: Other: netrin-1 value on admission to hospital

• Study Type: Interventional
• Enrollment (Actual): 238
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients over the age of 18
• diagnose ACS
• patients undergoing angiography

Exclusion Criteria:

• CVE history
• Neurological disease
• Pregnancy and Lactation
• Liver failure
• Diagnosed malignity
• Use of anticonvulsant and nephrotoxic medication
• Chronic kidney disease
• Not having angiography
• Developing acute renal failure after angiography
• Patients who rejected to participate were excluded.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: ACS GRUP; Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared. GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared.	Other: netrin-1 value on admission to hospital
Active Comparator: plasebo grup; It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.	Other: netrin-1 value on admission to hospital

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
serum netrin-1 value	Netrin-1 in plasma was measured by enzyme-linked immunosorbent assay (ELISA) (Mybıosource MBS044526 ) All assays were performed in duplicate. Plasma Netrin-1 is expressed in picograms (pg) per mg.	30 minute

Collaborators and Investigators

• Sponsor: Aksaray University Training and Research Hospital
• Investigators: Study Director: Hüseyin Mutlu, MD, Aksaray/Turkey

Study record dates

Study Major Dates

• Study Start (Actual): September 15, 2013
• Primary Completion (Actual): August 15, 2014
• Study Completion (Actual): June 15, 2018

Study Registration Dates

• First Submitted: June 18, 2019
• First Submitted That Met QC Criteria: July 18, 2019
• First Posted (Actual): July 19, 2019

Study Record Updates

• Last Update Posted (Actual): July 19, 2019
• Last Update Submitted That Met QC Criteria: July 18, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: netrin-1; acs; reperfuzion
• Additional Relevant MeSH Terms: Pathologic Processes; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Disease; Syndrome; Acute Coronary Syndrome
• Other Study ID Numbers: aksaray 2013-23

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No